Molecular and clinical oncology最新文献

{"title":"Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN^®) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer.","authors":"Tomoya Abe,&nbsp;Atsunobu Sagara,&nbsp;Daichi Okada,&nbsp;Kazumasa Matsuzaka","doi":"10.3892/mco.2023.2637","DOIUrl":"https://doi.org/10.3892/mco.2023.2637","url":null,"abstract":"<p><p>The present study is a safety survey of patients with human epidermal growth factor receptor type 2-positive, chemotherapy-naive breast cancer treated with trastuzumab plus paclitaxel at the Saitama Cancer Center (Saitama, Japan) between April 2018 and March 2022. The expression of infusion reaction (IR) and the effect on cardiac function were investigated in patients who switched from reference trastuzumab (HERCEPTIN^®) to biosimilar trastuzumab (Trastuzumab-NK) and continued treatment (switching group). The two groups (reference vs. biosimilar trastuzumab) had no significant difference in the expression of IR (P>0.999). In the switching group, IR associated with switching did not occur in all nine eligible patients. Left ventricular ejection fraction (LVEF) was used to assess cardiac function, and no patient in either group experienced a significant decrease in LVEF with treatment, meaning that there was no effect of switching on the decrease in LVEF. These results suggested that switching from reference to biosimilar trastuzumab may not have a significant effect on the frequency of IR expression or the occurrence of cardiac dysfunction.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 5","pages":"41"},"PeriodicalIF":1.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/b4/mco-18-05-02637.PMC10080020.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9274109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction of the skin‑effect dose of IMRT plan for patients with cancer in pelvic region.","authors":"Quang Bui Vinh,&nbsp;Soai Dang Quoc,&nbsp;Toan Hoang Van,&nbsp;Truong Vu,&nbsp;Tuyet Pham Thi","doi":"10.3892/mco.2023.2639","DOIUrl":"https://doi.org/10.3892/mco.2023.2639","url":null,"abstract":"<p><p>In the present study, it was aimed to investigate the optimized plan of radiotherapy with dose modulation in the pelvis to reduce the dose on the skin in patients having pelvic region radiotherapy. The series of images of 45 pelvic cancer patients were selected, intensity-modulated radiation therapy (IMRT) plan was made, the skin dose reduction was optimized, and evaluated verifying the plan verification. As a result, skin volume receiving dose ≥10, ≥20, ≥30, ≥40 and ≥50 Gy of the IMRT Skin plan were all less than those of the IMRT plan. Particularly, skin volumes receiving doses ≥20, ≥30, ≥40 and ≥50 Gy of the Skin IMRT plan were markedly lower than those of the IMRT plan, the reduction values were 8.76, 18.83, 46.84 and 100%, respectively. Furthermore, the Skin IMRT plan was no longer affected by the 50 Gy dose. In conclusion, the present study revealed that the skin's dose can be decreased with optimal plan processing; thus, this decrease of the skin's dose ensures the continuation of radiotherapy and improved life quality of the patient.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 5","pages":"43"},"PeriodicalIF":1.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/c1/mco-18-05-02639.PMC10080264.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9274110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemangioblastoma of the medulla oblongata that caused isolated fourth ventricle after stereotactic radiosurgery: A case report.","authors":"Yuya Hama,&nbsp;Takahiro Sasaki,&nbsp;Toshikazu Yamoto,&nbsp;Junya Fukai,&nbsp;Hiroki Nishibayashi,&nbsp;Naoyuki Nakao","doi":"10.3892/mco.2023.2633","DOIUrl":"https://doi.org/10.3892/mco.2023.2633","url":null,"abstract":"<p><p>Isolated fourth ventricle is a rare complication following shunt insertion of the lateral ventricles for hydrocephalus. The present report describes a rare case of a hemangioblastoma of the medulla oblongata that caused isolated fourth ventricle due to intraventricular deposition of fibrin. A 34-year-old man presented with headache a month before admission. Magnetic resonance imaging indicated multiple tumors in the medulla oblongata and the bilateral cerebellar hemisphere with surrounding edema, and the patient was diagnosed with hemangioblastoma. The patient began to develop progressive headache and nausea after stereotactic radiosurgery, and computed tomography showed obstructive hydrocephalus. Endoscopic third ventriculostomy was performed, and the intraoperative view of this showed that the walls of the lateral and third ventricles were covered with a white membrane-like substance. Endoscopic third ventriculostomy and then ventriculoperitoneal shunt did not improve the hydrocephalus. The patient's consciousness deteriorated due to isolated fourth ventricle and upward herniation. The patient underwent posterior fossa craniotomy and the tumor in the medulla oblongata was removed via a telovelar approach. Intraoperatively, the fourth ventricle was filled with a white membrane-like substance, which was surgically removed and pathologically diagnosed as fibrin. The patient's consciousness and obstructive hydrocephalus improved after surgery. The present case suggests that isolated fourth ventricle may occur after VP shunt placement for the hydrocephalus with hyperproteinorachia.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 5","pages":"37"},"PeriodicalIF":1.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/79/mco-18-05-02633.PMC10067790.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9311397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soluble PD‑L1 reflects cachexia status in patients with gastric cancer and is an independent prognostic marker for relapse‑free survival after radical surgery.","authors":"Yasunori Matsumoto,&nbsp;Takuma Sasaki,&nbsp;Masayuki Kano,&nbsp;Tadashi Shiraishi,&nbsp;Hiroshi Suito,&nbsp;Kentaro Murakami,&nbsp;Takeshi Toyozumi,&nbsp;Ryota Otsuka,&nbsp;Kazuya Kinoshita,&nbsp;Shinichiro Iida,&nbsp;Hiroki Morishita,&nbsp;Yuri Nishioka,&nbsp;Koichi Hayano,&nbsp;Yoshihiro Kurata,&nbsp;Hideki Hayashi,&nbsp;Hisahiro Matsubara","doi":"10.3892/mco.2023.2635","DOIUrl":"https://doi.org/10.3892/mco.2023.2635","url":null,"abstract":"<p><p>Soluble programmed death-ligand 1 (sPD-L1) levels can be used as a biomarker for gastric cancer (GC). However, comprehensive information regarding the sPD-L1 expression profiles and their association with cachexia in GC is lacking. Therefore, the present study evaluated the association between clinicopathological findings and sPD-L1 levels in patients with GC. Serum samples were collected from patients with GC during their first visit to Department of Esophageal-Gastro-Intestinal Surgery, Chiba University Hospital, Chiba, Japan (January 2012-December 2017; n=173), and sPD-L1 levels were measured using an enzyme-linked immunosorbent assay. Survival rates among 116 patients, excluding cases with preoperative chemotherapy or no radical procedures, were analyzed. sPD-L1 levels were associated with factors such as neutrophil-to-lymphocyte ratio, hemoglobin (Hb) and albumin (Alb) levels, total cholesterol and C-reactive protein (CRP) levels, and related to inflammation and nutrition in patients. Notably, the higher the number of applicable indicators related to cachexia (Hb <12 g/dl, Alb <3.2 g/dl, CRP >0.5 mg/dl and low body mass index) was, the higher the sPD-L1 value was. However, the pathological stage did not significantly differ between the groups. Clinicopathologically, there was no association with tumor depth, lymph node metastasis or vascular invasion; however, patients with the intestinal type had significantly higher sPD-L1 levels than patients with the diffuse type (P=0.032; Wilcoxon test). The overall survival did not significantly differ between the groups with low and high sPD-L1 levels; however, among patients who received radical treatment, the relapse-free survival was significantly worse in the high-sPD-L1-level group than in the low-sPD-L1-level group (P=0.025; log-rank test). Multivariate Cox regression analysis revealed that a high sPD-L1 concentration was a sign of poor prognosis, independent of pathological stage and cancer antigen CA19-9 (P=0.0029). Therefore, the present findings suggest that sPD-L1 can reflect cachexia status in patients with GC and may serve as a prognostic marker for relapse-free survival after radical GC surgery.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 5","pages":"39"},"PeriodicalIF":1.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/2a/mco-18-05-02635.PMC10074020.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9274111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory myofibroblastic tumor of the bladder: Computed tomographic features.","authors":"Pan Liang,&nbsp;Bing-Bing Zhu,&nbsp;Xiu-Chun Ren,&nbsp;Jian-Bo Gao","doi":"10.3892/mco.2023.2636","DOIUrl":"https://doi.org/10.3892/mco.2023.2636","url":null,"abstract":"<p><p>Inflammatory myofibroblastic tumor (IMT) is a rare tumor with intermediate biologic potential, in which lack of understanding often poses difficulties in preoperative diagnosis and treatment. The aim of the present study was to characterize the computed tomography (CT) features of the bladder IMT. The CT images of nine pathologically confirmed bladder IMT were retrospectively reviewed. All patients underwent both unenhanced CT and contrast-enhanced CT. The diameter, location, contour, growth pattern, margin, boundary, density and enhancement pattern of the lesions were assessed. The mean Ki67 value of an irregular blood clot was 18% and that of no blood clot was 12%. A total of eight (89%) patients had one tumor and 1 (11%) patient had multiple tumors. An endophytic growth pattern was observed in 4 (44%) patients, an exophytic growth pattern in 2 (22%) patients, and a mixed growth pattern in 3 (33%) patients. The tumor manifests morphologically as either polypoid (n=5), or cauliflower-like (n=1) soft-tissue mass with a wide base in the cavity, or a limited thick-walled (n=3). The tumor margins were smooth (n=8) or lobulated (n=1), and the tumor boundaries were either clear (n=7) or ill-defined (n=2). The lesions showed either ring-shaped (n=3) or heterogeneous (n=6). The polypoid and cauliflower-like soft-tissue mass showed a symmetrical change in the center of the lesion after enhancement. The bladder IMT is mostly a single polypoid nodule in the superior wall, mostly endophytic growth, with ring-haped enhancement and symmetrical change after enhancement as its characteristic manifestations.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 5","pages":"40"},"PeriodicalIF":1.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074019/pdf/mco-18-05-02636.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9279482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoblastoma of the patella, a rare benign bone tumor with an uncommon site: A case report.","authors":"Feng Li,&nbsp;Yongjie Qiao,&nbsp;Shenghu Zhou,&nbsp;Xiaoyang Song,&nbsp;Haoqiang Zhang","doi":"10.3892/mco.2023.2638","DOIUrl":"https://doi.org/10.3892/mco.2023.2638","url":null,"abstract":"<p><p>Osteoblastoma is a rare, benign, bone-forming tumor that is frequently observed in the spine and long tubular bones. There are very few reports available on osteoblastoma of the patella. The present study reported an extremely rare case of a 22-year-old male adult who presented with an osteoblastoma of the patella. He was treated via intralesional curettage of the patella with subsequent bone grafting. After the intervention, he made an uneventful recovery with no recurrence after a follow-up of 2 years. Making an accurate diagnosis of osteoblastoma of the patella is challenging and important for determining the correct treatment modality and prognosis, therefore, the present case may be helpful in the diagnosis and treatment of osteoblastoma of the patella.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 5","pages":"42"},"PeriodicalIF":1.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/34/mco-18-05-02638.PMC10080022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9336699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy in malignant peritoneal mesothelioma (Review).","authors":"Sabah Alaklabi,&nbsp;Arya Mariam Roy,&nbsp;Joseph J Skitzki,&nbsp;Renuka Iyer","doi":"10.3892/mco.2023.2627","DOIUrl":"https://doi.org/10.3892/mco.2023.2627","url":null,"abstract":"<p><p>Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer. Immune checkpoint inhibitors (ICIs) have been incorporated into the treatment regimens for patients with various solid tumors. Mesothelioma trials revealed encouraging efficacy; however, patients with peritoneal mesothelioma are usually excluded, slowing the progress of improving the treatment of this aggressive cancer and compelling oncologist to rely on retrospective studies despite their flaws and limitations. Currently, there is no consensus on the role of ICIs in the treatment of malignant peritoneal mesothelioma (MPeM). The present review discusses data from clinical studies that examined immunotherapy in MPeM and evaluates what is known about the relevance of the tumor microenvironment and clinically validated biomarkers for ICIs efficacy. Furthermore, a proposed strategy for utilizing immunotherapy in treating MPeM is discussed.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 4","pages":"31"},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995593/pdf/mco-18-04-02627.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9155698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insight on common forms of cutaneous head and neck carcinoma (Review).","authors":"Doriana Cristea-Ene Iancu,&nbsp;Ana Fulga,&nbsp;Doina Vesa,&nbsp;Constantin Stan,&nbsp;Andrei Zenovia,&nbsp;Florin Bujoreanu,&nbsp;Alin Ionut Piraianu,&nbsp;Mihaela Ionela Sarbu,&nbsp;Alin Laurentiu Tatu","doi":"10.3892/mco.2023.2624","DOIUrl":"https://doi.org/10.3892/mco.2023.2624","url":null,"abstract":"To improve the outcome and quality of life for patients with head and neck carcinoma, an increasing amount of research has been performed on the particularities of this type of cancer and its treatment methods. Starting from clinical aspects, including histology and imaging features, up-to-date studies from different parts of the world have determined new data leading to a better understanding of the mechanisms behind the disease and proposed new treatment protocols. The head and neck areas are predisposed to almost all skin neoplasms, most commonly those related to ultraviolet exposure. Squamous cell carcinoma and basal cell carcinoma account for almost 90% of non-melanoma skin cancers in this region; therefore, reviewing the literature on cutaneous carcinomas of the head and neck area and sharing particular aspects of their physiopathology are beneficial for a great number of patients.","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 4","pages":"28"},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995598/pdf/mco-18-04-02624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9155701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer.","authors":"Yao Liang,&nbsp;Osamu Maeda,&nbsp;Kazushi Miyata,&nbsp;Mitsuro Kanda,&nbsp;Dai Shimizu,&nbsp;Shizuki Sugita,&nbsp;Tohru Okada,&nbsp;Junji Ito,&nbsp;Mariko Kawamura,&nbsp;Shunichi Ishihara,&nbsp;Masahiro Nakatochi,&nbsp;Masahiko Ando,&nbsp;Yasuhiro Kodera,&nbsp;Yuichi Ando","doi":"10.3892/mco.2023.2630","DOIUrl":"https://doi.org/10.3892/mco.2023.2630","url":null,"abstract":"<p><p>The present study aimed to assess the feasibility of global standard chemoradiotherapy (CRT) followed by surgery in patients with esophageal cancer. A prospective study was conducted at Nagoya University Hospital (Nagoya, Japan) to evaluate global standard CRT followed by surgery in patients with esophageal cancer. The CRT regimen consisted of 75 mg/m² cisplatin on day 1 and 1,000 mg/m² fluorouracil daily on days 1-4 given twice 4 weeks apart together with concurrent esophageal irradiation starting on day 1 (group A). For comparison, 17 patients with esophageal cancer who had received the same chemotherapy regimen but with lower drug doses were retrospectively reviewed: 70 mg/m² cisplatin on day 1 and 700 mg/m² fluorouracil daily on days 1-4 given twice 4 weeks apart together with concurrent esophageal irradiation starting on day 1 (group B). Grade 3 or worse adverse events were observed in 9 of the 12 patients (75%) in group A and in 5 of the 17 patients (29%) in group B. The patients in group A were more likely to experience grade 3 or worse neutropenia (50%) than those in group B (6%). No febrile neutropenia or treatment-related deaths occurred in either group. A total of 11 patients (92%) in group A and 16 patients (94%) in group B subsequently underwent an esophagectomy, and 9 (82%) and 14 (88%) of these patients, respectively, achieved microscopically margin-negative resection (R0 resection). In conclusion, global standard CRT was more likely to cause severe but manageable adverse events. There was no apparent difference in the R0 resection rate or postoperative complications between the two treatments. This clinical trial was registered at the Japan Registry of Clinical Trials (trial registration number: jRCT1041180004) on September 11, 2018.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 4","pages":"34"},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/ce/mco-18-04-02630.PMC10011946.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9130704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective analysis of <i>Porphyromonas gingivalis</i> in patients with nasopharyngeal carcinoma in central China.","authors":"Bianli Gu,&nbsp;Yuehui Wang,&nbsp;Jianwei Huang,&nbsp;Jingyi Guo,&nbsp;Lixia Ma,&nbsp;Yijun Qi,&nbsp;Shegan Gao","doi":"10.3892/mco.2023.2628","DOIUrl":"https://doi.org/10.3892/mco.2023.2628","url":null,"abstract":"<p><p>Little is known about the presence and possible role of <i>Porphyromonas gingivalis</i> (<i>P. gingivalis</i>) in nasopharyngeal carcinoma (NPC), its co-infection with Epstein-Barr virus (EBV), or their association with clinical characteristics of patients with NPC in Central China, where NPC is non-endemic. A total of 45 NPC formalin-fixed paraffin-embedded (FFPE) tissues were retrospectively analyzed using immunohistochemistry (IHC) and a nested PCR combined with DNA sequencing to detect the presence of <i>P. gingivalis</i>, and using reverse transcription-quantitative PCR to detect the presence of EBV. Clinical data including EBV and <i>P. gingivalis</i> status were associated with overall survival (OS). All tumors were undifferentiated, non-keratinizing carcinomas, of which 40/45 (88.9%) were positive for EBV (EBV⁺), 26/45 (57.8%) were positive for <i>P. gingivalis</i> (by IHC), and 7/45 (15.6%) were positive for <i>P. gingivalis</i> DNA (<i>P. gingivalis</i> ⁺). All seven <i>P. gingivalis</i> DNA-positive NPCs were co-infected with EBV. The 5-year survival rates of the patients with EBV^-/<i>P. gingivalis</i> ^-, EBV⁺/<i>P. gingivalis</i> ^-, and EBV⁺/<i>P. gingivalis</i> ⁺ tumors were 60.0% (3/5), 39.4% (13/33) and 42.9% (3/7), respectively. No significant difference was found between the OS of NPC patients among the different infection groups (P=0.793). In conclusion, to the best of our knowledge, this is the first study to describe and confirm the presence of <i>P. gingivalis</i> in FFPE tissues from patients with NPC. <i>P. gingivalis</i> was found to co-exist with EBV in NPC tumor tissues, but is not etiologically relevant to NPC in non-endemic areas, such as Central China.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"18 4","pages":"32"},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/7e/mco-18-04-02628.PMC9995702.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9454250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}